Halozyme Therapeutics Surpasses Analyst Price Target, Analysts Weigh In
Recently, shares of Halozyme Therapeutics Inc (Symbol: HALO) exceeded the average analyst 12-month target price of $68.12, trading at $70.14 per share. When a stock reaches an analyst’s target, they typically have two options: downgrade based on valuation or adjust their target price upward. Analyst reactions may also consider the underlying developments propelling the stock price higher, which could justify a revised target.
Analyst Target Overview
Eight analysts contribute to the average for Halozyme Therapeutics, but this figure represents a mere mathematical average. For instance, while one analyst sets a target at $58.00, another has a more optimistic view at $78.00. The standard deviation among these targets stands at $8.542.
Evaluating Investor Sentiment
The purpose of examining the average price target lies in understanding the collective insights from various analysts. With HALO trading above the average target of $68.12, it signals to investors to reassess the company. Key questions arise: Is the current price just a milestone on a path to a higher target, or is it time to consider reducing exposure?
Current Analyst Ratings for Halozyme Therapeutics
| Recent HALO Analyst Ratings Breakdown | ||||
|---|---|---|---|---|
| » | Current | 1 Month Ago | 2 Months Ago | 3 Months Ago |
| Strong buy ratings: | 5 | 5 | 5 | 5 |
| Buy ratings: | 0 | 0 | 0 | 0 |
| Hold ratings: | 3 | 3 | 4 | 4 |
| Sell ratings: | 0 | 0 | 0 | 0 |
| Strong sell ratings: | 0 | 0 | 0 | 0 |
| Average rating: | 1.75 | 1.75 | 1.89 | 1.89 |
The average rating of 1.75 indicates a generally favorable outlook, with 1 representing Strong Buy and 5 representing Strong Sell. This analysis uses data from Zacks Investment Research via Quandl.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
